AdAlta
next generation protein therapeutics

ASX Announcement

AdAlta shareholder information sessions

MELBOURNE Australia, 15th October, 2018: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to invite shareholders to attend information briefing sessions to discuss the latest manufacturing update on AD-214.

Shareholder briefing sessions:

The following sessions are available to those shareholders able to attend:

Perth	Friday 26th October, 11:30am Patersons Stockbroking: Level 23, Exchange Tower, 2 The Esplanade, Perth
Sydney:	Monday, 29th October, 11:00am FB Rice: Level 23, 44 Market Street, Sydney
Melbourne:	Tuesday, 30th October, 1pm CSBC: Level 14, 330 Collins Street, Melbourne
Brisbane:	Wednesday 31st October, 12:30pm Morgans: Level 29, Riverside Centre, 123 Eagle Street Brisbane QLD 4000

Please RSVP to attend

Shareholders wishing to register interest in attending one of the events outlined below should RSVP by either:

- Phoning Ebony Fietz on +61 0409 018 525
- Using the Contact Us form on the AdAlta website at http://adalta.com.au/contact-us/
- Or emailing enquiries@adalta.com.au.

At the time of RSVP, please note your: name, email, contact number and which briefing session is of interest (Perth, Sydney, Melbourne or Brisbane).

The AdAlta team looks forward to seeing those shareholders who are able to attend.

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited
Sam Cobb, CEO
Tel: +61 (0)3 9479 5159
E: s.cobb@adalta.com.au